Skip Navigation LinksHome > January 15, 2014 - Volume 97 - Issue 1 > Crossmatch-Positive Liver Transplantation in Patients Receiv...
Transplantation:
doi: 10.1097/TP.0b013e3182a688c0
Clinical and Translational Research

Crossmatch-Positive Liver Transplantation in Patients Receiving Thymoglobulin-Rituximab Induction

Kubal, Chandrashekhar A.1,5; Mangus, Richard S.1; Saxena, Romil2; Lobashevsky, Andrew3; Higgins, Nancy3; Agarwal, Avinash4; Fridell, Jonathan A.1; Tector, A. Joseph1

Collapse Box

Abstract

Background: Positive crossmatch (CM) in liver transplantation (LT) is associated with worse outcomes. Role of induction immunosuppression in this setting remains to be studied.

Methods: One thousand consecutive LT patients receiving rabbit antithymocyte globulin±rituximab induction were studied. Pretransplantation sera of 55 CM-positive (CM+) patients were tested for C1q-fixing donor-specific antibodies (DSA). Diagnosis of antibody-mediated rejection required presence of diffuse vascular C4d expression on liver biopsies.

Results: CM was positive in 112 (11%) recipients. Antibody-mediated rejection was observed in 3 (0.03%) patients, whereas acute cellular rejection (ACR) occurred in 31 (3%) patients. CM+ status was associated with a higher incidence of ACR (9% in CM+ vs. 2% in CM-negative [CM]; P<0.01) and chronic rejection (4% in CM+ vs. 1% in CM; P<0.01). Graft survival was slightly lower in CM+ patients (at 1 year; 85% in CM+ vs. 89% in CM; P=0.26). Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis as a group had a tendency toward CM+ status as well as developing ACR. Upon multivariate analysis, CM status was the strongest predictor of ACR (B=1.14; P=0.02). Only half of CM+ patients harbored C1q-fixing DSA. Presence of C1q-fixing DSA was not associated with increased incidence of ACR.

Conclusions: In LT, CM+ status is associated with an increased incidence of acute rejection, chronic rejection, and slightly worse graft survival. With the use of rabbit antithymocyte globulin±rituximab induction, overall low rejection rates can be achieved in CM+ LT.

© 2014 by Lippincott Williams & Wilkins

 

 

 

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.